BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

245 related articles for article (PubMed ID: 31685780)

  • 1. Identification and Assessments of Novel and Potent Small-Molecule Inhibitors of EED-EZH2 Interaction of Polycomb Repressive Complex 2 by Computational Methods and Biological Evaluations.
    Zhu K; Du D; Yang R; Tao H; Zhang H
    Chem Pharm Bull (Tokyo); 2020 Jan; 68(1):58-63. PubMed ID: 31685780
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Astemizole arrests the proliferation of cancer cells by disrupting the EZH2-EED interaction of polycomb repressive complex 2.
    Kong X; Chen L; Jiao L; Jiang X; Lian F; Lu J; Zhu K; Du D; Liu J; Ding H; Zhang N; Shen J; Zheng M; Chen K; Liu X; Jiang H; Luo C
    J Med Chem; 2014 Nov; 57(22):9512-21. PubMed ID: 25369470
    [TBL] [Abstract][Full Text] [Related]  

  • 3. An allosteric PRC2 inhibitor targeting the H3K27me3 binding pocket of EED.
    Qi W; Zhao K; Gu J; Huang Y; Wang Y; Zhang H; Zhang M; Zhang J; Yu Z; Li L; Teng L; Chuai S; Zhang C; Zhao M; Chan H; Chen Z; Fang D; Fei Q; Feng L; Feng L; Gao Y; Ge H; Ge X; Li G; Lingel A; Lin Y; Liu Y; Luo F; Shi M; Wang L; Wang Z; Yu Y; Zeng J; Zeng C; Zhang L; Zhang Q; Zhou S; Oyang C; Atadja P; Li E
    Nat Chem Biol; 2017 Apr; 13(4):381-388. PubMed ID: 28135235
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Identification of catalytic and non-catalytic activity inhibitors against PRC2-EZH2 complex through multiple high-throughput screening campaigns.
    Zhou Y; Du DH; Wang J; Cai XQ; Deng AX; Nosjean O; Boutin JA; Renard P; Yang DH; Luo C; Wang MW
    Chem Biol Drug Des; 2020 Oct; 96(4):1024-1051. PubMed ID: 32394628
    [TBL] [Abstract][Full Text] [Related]  

  • 5. EED-Targeted PROTACs Degrade EED, EZH2, and SUZ12 in the PRC2 Complex.
    Hsu JH; Rasmusson T; Robinson J; Pachl F; Read J; Kawatkar S; O' Donovan DH; Bagal S; Code E; Rawlins P; Argyrou A; Tomlinson R; Gao N; Zhu X; Chiarparin E; Jacques K; Shen M; Woods H; Bednarski E; Wilson DM; Drew L; Castaldi MP; Fawell S; Bloecher A
    Cell Chem Biol; 2020 Jan; 27(1):41-46.e17. PubMed ID: 31786184
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Binding Modes of Small-Molecule Inhibitors to the EED Pocket of PRC2.
    Huang D; Tian S; Qi Y; Zhang JZH
    Chemphyschem; 2020 Feb; 21(3):263-271. PubMed ID: 31816138
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Structure-Guided Development of Small-Molecule PRC2 Inhibitors Targeting EZH2-EED Interaction.
    Du D; Xu D; Zhu L; Stazi G; Zwergel C; Liu Y; Luo Z; Li Y; Zhang Y; Zhu K; Ding Y; Liu J; Fan S; Zhao K; Zhang N; Kong X; Jiang H; Chen K; Zhao K; Valente S; Min J; Duan W; Luo C
    J Med Chem; 2021 Jun; 64(12):8194-8207. PubMed ID: 34077206
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Rapid Identification of Novel Allosteric PRC2 Inhibitors.
    Read JA; Tart J; Rawlins PB; Gregson C; Jones K; Gao N; Zhu X; Tomlinson R; Code E; Cheung T; Chen H; Kawatkar SP; Bloecher A; Bagal S; O'Donovan DH; Robinson J
    ACS Chem Biol; 2019 Oct; 14(10):2134-2140. PubMed ID: 31525019
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Diverse, Potent, and Efficacious Inhibitors That Target the EED Subunit of the Polycomb Repressive Complex 2 Methyltransferase.
    Bagal SK; Gregson C; O' Donovan DH; Pike KG; Bloecher A; Barton P; Borodovsky A; Code E; Fillery SM; Hsu JH; Kawatkar SP; Li C; Longmire D; Nai Y; Nash SC; Pike A; Robinson J; Read JA; Rawlins PB; Shen M; Tang J; Wang P; Woods H; Williamson B
    J Med Chem; 2021 Dec; 64(23):17146-17183. PubMed ID: 34807608
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Identification of novel EED-EZH2 PPI inhibitors using an in silico fragment mapping method.
    Misawa K; Yamaotsu N; Hirono S
    J Comput Aided Mol Des; 2021 May; 35(5):601-611. PubMed ID: 33635506
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Wedelolactone disrupts the interaction of EZH2-EED complex and inhibits PRC2-dependent cancer.
    Chen H; Gao S; Li J; Liu D; Sheng C; Yao C; Jiang W; Wu J; Chen S; Huang W
    Oncotarget; 2015 May; 6(15):13049-59. PubMed ID: 25944687
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Embryonic Ectoderm Development (EED) as a Novel Target for Cancer Treatment.
    Cook N; Chen J; Zhou J; Wu D
    Curr Top Med Chem; 2021; 21(31):2771-2777. PubMed ID: 34544341
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Small Molecule Approaches for Targeting the Polycomb Repressive Complex 2 (PRC2) in Cancer.
    Martin MC; Zeng G; Yu J; Schiltz GE
    J Med Chem; 2020 Dec; 63(24):15344-15370. PubMed ID: 33283516
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Discovery and Molecular Basis of a Diverse Set of Polycomb Repressive Complex 2 Inhibitors Recognition by EED.
    Li L; Zhang H; Zhang M; Zhao M; Feng L; Luo X; Gao Z; Huang Y; Ardayfio O; Zhang JH; Lin Y; Fan H; Mi Y; Li G; Liu L; Feng L; Luo F; Teng L; Qi W; Ottl J; Lingel A; Bussiere DE; Yu Z; Atadja P; Lu C; Li E; Gu J; Zhao K
    PLoS One; 2017; 12(1):e0169855. PubMed ID: 28072869
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Degradation of Polycomb Repressive Complex 2 with an EED-Targeted Bivalent Chemical Degrader.
    Potjewyd F; Turner AW; Beri J; Rectenwald JM; Norris-Drouin JL; Cholensky SH; Margolis DM; Pearce KH; Herring LE; James LI
    Cell Chem Biol; 2020 Jan; 27(1):47-56.e15. PubMed ID: 31831267
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Identification of EZH2 and EZH1 small molecule inhibitors with selective impact on diffuse large B cell lymphoma cell growth.
    Garapaty-Rao S; Nasveschuk C; Gagnon A; Chan EY; Sandy P; Busby J; Balasubramanian S; Campbell R; Zhao F; Bergeron L; Audia JE; Albrecht BK; Harmange JC; Cummings R; Trojer P
    Chem Biol; 2013 Nov; 20(11):1329-39. PubMed ID: 24183969
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Polycomb Repressive Complex 2 Modulation through the Development of EZH2-EED Interaction Inhibitors and EED Binders.
    Tomassi S; Romanelli A; Zwergel C; Valente S; Mai A
    J Med Chem; 2021 Aug; 64(16):11774-11797. PubMed ID: 34351144
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The EED protein-protein interaction inhibitor A-395 inactivates the PRC2 complex.
    He Y; Selvaraju S; Curtin ML; Jakob CG; Zhu H; Comess KM; Shaw B; The J; Lima-Fernandes E; Szewczyk MM; Cheng D; Klinge KL; Li HQ; Pliushchev M; Algire MA; Maag D; Guo J; Dietrich J; Panchal SC; Petros AM; Sweis RF; Torrent M; Bigelow LJ; Senisterra G; Li F; Kennedy S; Wu Q; Osterling DJ; Lindley DJ; Gao W; Galasinski S; Barsyte-Lovejoy D; Vedadi M; Buchanan FG; Arrowsmith CH; Chiang GG; Sun C; Pappano WN
    Nat Chem Biol; 2017 Apr; 13(4):389-395. PubMed ID: 28135237
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Targeted disruption of the EZH2-EED complex inhibits EZH2-dependent cancer.
    Kim W; Bird GH; Neff T; Guo G; Kerenyi MA; Walensky LD; Orkin SH
    Nat Chem Biol; 2013 Oct; 9(10):643-50. PubMed ID: 23974116
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Identification of SET/EED dual binders as innovative PRC2 inhibitors.
    Catalano R; Maruca A; Rocca R; Tassone P; Panzarella G; Costa G; Ortuso F; Alcaro S
    Future Med Chem; 2022 May; 14(9):609-621. PubMed ID: 35348013
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 13.